News

Bionovo expects to grant its underwriters a 30-day option to purchase up to 1.71 million shares at the public offering price to cover over-allotments, if any. BMO Capital

The company is aiming to become the first to offer chronic pain sufferers a patch that provides sustained-release oxycodone into the bloodstream. Dr Esra Ogru, executive vice president

During the two separately scheduled pre-NDA meetings, Pipex reviewed with the FDA the format and content of Pipex's planned new drug application (NDA) submission of preclinical, clinical, manufacturing,

According to the company, this positive European Committee for Medicinal Products for Human Use (CHMP) opinion will be elevated to the European Commission where a likely favorable ruling

The compound, LXR-623, had been in Phase I testing for the treatment of atherosclerosis. While LXR-623 demonstrated efficacy on biomarkers for atherosclerosis, it had an unfavorable profile for

Data was presented at the 47th annual interscience conference on antimicrobial agents and chemotherapy conference showing that ulifloxacin, the active metabolite of prulifloxacin, Optimer's prodrug antibiotic product candidate,

Results demonstrated that the modified adenovector induced anti-tumor responses and limited expression of TNF in normal tissue. These highly selective adenovectors may provide the basis for a potentially

The system devices advisory panel also recommended the development of additional safety data as a basis for expanding the indicated use to include adult patients. Dr Eli Pines,

Findings show that people with type II diabetes in Europe had insulin initiated at a mean HbA1c of 9.6% and more than 12 months prior to initiation the